Fate Therapeutics annual revenue
2011
2012
2013
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Fate Therapeutics Revenue Growth & History (FATE)
Fate Therapeutics reported $6.6M in revenue for fiscal 2025, a decrease of 51.24% from the previous fiscal year.
View full Fate Therapeutics company overviewFate Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.6M | −$7.0M | −51.24% |
| 2024 | 2024-12-31 | $13.6M | −$49.9M | −78.55% |
| 2023 | 2023-12-31 | $63.5M | −$32.8M | −34.03% |
| 2022 | 2022-12-31 | $96.3M | $40.5M | +72.44% |
| 2021 | 2021-12-31 | $55.8M | $24.4M | +77.66% |
| 2020 | 2020-12-31 | $31.4M | $20.8M | +194.33% |
| 2019 | 2019-12-31 | $10.7M | $5.9M | +125.32% |
| 2018 | 2018-12-31 | $4.7M | $634,000 | +15.44% |
| 2017 | 2017-12-31 | $4.1M | −$296,000 | −6.72% |
| 2016 | 2016-12-31 | $4.4M | $2.0M | +81.08% |
| 2015 | 2015-12-31 | $2.4M | — | — |
| 2013 | 2013-12-31 | $971,000 | −$1.7M | −63.63% |
| 2012 | 2012-12-31 | $2.7M | $1.5M | +128.21% |
| 2011 | 2011-12-31 | $1.2M | — | — |
Fate Therapeutics quarterly revenue
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.1M | $175,000 | +9.18% |
| Q1 2026 | 2026-03-31 | $1.3M | −$330,000 | −20.26% |
| Q4 2025 | 2025-12-31 | $1.4M | −$491,000 | −26.40% |
| Q3 2025 | 2025-09-30 | $1.7M | −$1.3M | −43.36% |
| Q2 2025 | 2025-06-30 | $1.9M | −$4.9M | −71.84% |
| Q1 2025 | 2025-03-31 | $1.6M | −$296,000 | −15.38% |
| Q4 2024 | 2024-12-31 | $1.9M | $184,000 | +10.98% |
| Q3 2024 | 2024-09-30 | $3.1M | $1.1M | +58.13% |
| Q2 2024 | 2024-06-30 | $6.8M | $5.8M | +625.83% |
| Q1 2024 | 2024-03-31 | $1.9M | −$57.1M | −96.74% |
| Q4 2023 | 2023-12-31 | $1.7M | −$42.7M | −96.22% |
| Q3 2023 | 2023-09-30 | $1.9M | −$13.0M | −87.02% |
| Q2 2023 | 2023-06-30 | $933,000 | −$17.6M | −94.97% |
| Q1 2023 | 2023-03-31 | $59.0M | $40.6M | +220.30% |
| Q4 2022 | 2022-12-31 | $44.4M | $27.3M | +159.89% |
| Q3 2022 | 2022-09-30 | $15.0M | $756,000 | +5.31% |
| Q2 2022 | 2022-06-30 | $18.5M | $5.1M | +38.30% |
| Q1 2022 | 2022-03-31 | $18.4M | $7.3M | +65.27% |
| Q4 2021 | 2021-12-31 | $17.1M | $1.2M | +7.37% |
| Q3 2021 | 2021-09-30 | $14.2M | $6.7M | +88.21% |
| Q2 2021 | 2021-06-30 | $13.4M | $7.9M | +145.42% |
| Q1 2021 | 2021-03-31 | $11.1M | $8.6M | +343.02% |
| Q4 2020 | 2020-12-31 | $15.9M | $13.1M | +467.31% |
| Q3 2020 | 2020-09-30 | $7.6M | $5.1M | +211.16% |
| Q2 2020 | 2020-06-30 | $5.5M | $2.6M | +94.00% |
| Q1 2020 | 2020-03-31 | $2.5M | −$117,000 | −4.45% |
| Q4 2019 | 2019-12-31 | $2.8M | $1.1M | +68.69% |
| Q3 2019 | 2019-09-30 | $2.4M | $1.4M | +136.74% |
| Q2 2019 | 2019-06-30 | $2.8M | $1.8M | +174.29% |
| Q1 2019 | 2019-03-31 | $2.6M | $1.6M | +156.53% |
| Q4 2018 | 2018-12-31 | $1.7M | $634,000 | +61.73% |
| Q3 2018 | 2018-09-30 | $1.0M | $0 | 0.00% |
| Q2 2018 | 2018-06-30 | $1.0M | $1,000 | +0.10% |
| Q1 2018 | 2018-03-31 | $1.0M | −$1,000 | −0.10% |
| Q4 2017 | 2017-12-31 | $1.0M | $0 | 0.00% |
| Q3 2017 | 2017-09-30 | $1.0M | $0 | 0.00% |
| Q2 2017 | 2017-06-30 | $1.0M | −$1,000 | −0.10% |
| Q1 2017 | 2017-03-31 | $1.0M | −$295,000 | −22.31% |
| Q4 2016 | 2016-12-31 | $1.0M | −$49,000 | −4.55% |
| Q3 2016 | 2016-09-30 | $1.0M | $0 | 0.00% |
| Q2 2016 | 2016-06-30 | $1.0M | $698,000 | +212.16% |
| Q1 2016 | 2016-03-31 | $1.3M | — | — |
| Q4 2015 | 2015-12-31 | $1.1M | — | — |
| Q3 2015 | 2015-09-30 | $1.0M | — | — |
| Q2 2015 | 2015-06-30 | $329,000 | — | — |
| Q4 2013 | 2013-12-31 | $0 | −$643,000 | −100.00% |
| Q3 2013 | 2013-09-30 | $209,000 | −$319,000 | −60.42% |
| Q2 2013 | 2013-06-30 | $290,000 | −$791,000 | −73.17% |
| Q1 2013 | 2013-03-31 | $472,000 | $54,000 | +12.92% |
| Q4 2012 | 2012-12-31 | $643,000 | — | — |
| Q3 2012 | 2012-09-30 | $528,000 | — | — |
| Q2 2012 | 2012-06-30 | $1.1M | — | — |
| Q1 2012 | 2012-03-31 | $418,000 | — | — |
Fate Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue declined from $31.4M to $6.6M, a compound annual decline of 26.71%. Fate Therapeutics's latest reported quarter, Q2 2026, generated $2.1M in revenue, an increase of 9.18% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Fate Therapeutics source filings ↗Community posts
Fate Therapeutics wins $15 million grant for lupus-nephritis trial
Fate Therapeutics ($FATE) received a $15 million grant from the California Institute for Regenerative Medicine to support RECLAIM-LN, a Phase 2 study of FT819. The experimental off-the-shelf CAR-T treatment will be evaluated in approximatel ...
